CancerVaccines Market, By Type (Preventive and Therapeutic), By Technology(Subunit Vaccines, Live Attenuated Vaccines, and Others), and By Application(Cervical Cancer, Prostate Cancer, and Others) - Global Industry Insights,Trends, Outlook, and Opportunity Analysis, 2018-2026
Cancer is the second leadingcause of morbidity and mortality worldwide. Major cause of cancer is genemutation and rarely due to inherited genes. On the basis of the type of cell itinitiates to form cancerous with, it is divided into carcinoma, lymphomas, leukaemias,brain tumors, and sarcomas. According to World Health Organization (WHO), 2017,nearly 1 in 6 deaths is due to cancer globally and around 70% of deaths fromcancer occur in low- and middle-income countries. Moreover, it is projectedthat for next two decades, 70% of new cases are expected to be diagnosedglobally. Advent of cancer vaccines can significantly reduce this numbers andlead a cancer-free life for the global population.
Development of new vaccines fortreatment of different cancers is expected to fuel growth of the cancervaccines market over the forecast period
Manufacturers in the cancervaccines market are focusing on developing new vaccines in order to treatvarious cancers. Through this, they are expected to gain a competitive edge inthe market and increase their market share. For instance, in November 2019, NECCorporation and VAXIMM AG, collaborated for the development of novel neoantigencancer vaccines.
Also in July 2019, BoehringerIngelheim International GmbH., announced the acquisition of AMAL TherapeuticsSA, a company focused development of cancer immunotherapy and cancer vaccinesby its KISIMA technology. The acquisition is expected to enhance Boehringer’scancer portfolio and its cancer vaccine platform.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1209
Gilead Science Inc., in 2017,acquired Kite Pharma Inc., which is involved in development of different typeof immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated withPharmaceutical Product Development, LLC (PPD), in order to conduct itsfirst-in-human clinical trial for its cancer vaccine for metastatic colorectalcancer.
Furthermore, BioNTech developedRNA vaccines for mutations caused due to cancer. RNA vaccine exposes cancercell to antigen, which is recognized by the immune system. On the other hand,Scancell’s DNA vaccine forces cancerous cell to express two antigens – gp100and TRP-2 stimulating a strong T cell response.
In 2017, Jonsson ComprehensiveCancer Center and the Brain Tumor Center at the University of California LosAngeles (UCLA), was designated a Specialized Program of Research Excellence(SPORE) by the National Cancer Institute. The program is expected to supportresearch into prevention, detection, and treatment of cancers and will promoteco-operation among scientist in different disciplines, and also help totranslate basic research from laboratories to clinical trials more quickly andeffectively. Such recognition by national organizations is expected to supportresearch in cancer vaccines.
According to a research fromUniversity of Pittsburgh School of Medicine, in 2017, a high dose flu vaccinecan be used to treat people aged between 54–64 years with chronic conditionsuch as heart disease, lung disease, diabetes, and cancer. The study is recommendedfor clinical trials in geriatric population.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/cancer-vaccines-market-1209
Also, in 2017, Swiss Biotech,developed VXM01 — an attenuated bacterial vaccine modified to express vascularendothelial growth factor receptor-2 (VEGFR2), stimulates cytotoxic (killer) Tcells, which will destroy cells in the vasculature feeding tumor and allowgreater infiltration of immune cells. This vaccine is expected to be used fortreatment in colorectal cancer and glioblastoma.
In August 2017, Imugene Limitedannounced the entry of its anti-cancer vaccine, HER-Vaxx for gastric cancer in1b/2 clinical study and the phase 2 is expected to start soon.
Increasing prevalence andincidence of different cancers is expected to favor growth of the cancervaccines market
According to WHO, in 2015, about8.8 million people died from cancer. Moreover, tobacco related cancers wasresponsible for 22% deaths, lung cancer accounted for 1.69 million deaths,liver cancer led to 788,000 deaths. Colorectal, stomach, and breast cancer areestimated to cause 774,000, 754,000, and 571,000 deaths, worldwide. Increasingprevalence is a major driving factor to fuel growth of the cancer vaccinesmarket.
According to the American CancerSociety, 2017, cancer is the second most common cause of death in the U.S.,which accounts for nearly 1 out of every 4 deaths.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1209
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
